Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli, MD PhD, Gerhard Zugmaier, Noemi Mergen, MD, Peter Bader, MD, Sima Jeha, MD, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD, Benoit Brethon, MD, Claudia Rössig, William Kormany, MD, Puneeth Viswagnachar, Christiane Chen-Santel

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141336

Published: 2020

Journal Articles

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

Elad Jacoby, MD, Sara Ghorashian, FRCPath, PhD, Britta Julia Vormoor, MD, Barbara De Moerloose, MD, Nicole Bodmer, Michael Maschan, MD, Asaf David Yanir, MD, Bella Bielorai, MD, Srdan Rogosic, Olga Molostova, MD, Claudia Rossig, Amos Toren, MD PhD, Arend von Stackelberg, MD, Jean-Pierre Bourquin, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141940

Published: 2020

Journal Articles

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Fotini Vogiatzi, PhD, Kristina Müller, Dorothee Winterberg, Thies Rösner, PhD, Lennart Lenk, PhD, Gunnar Cario, MD PhD, Martin Schrappe, MDPhD, Andreas E. Kulozik, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140270

Published: 2020

Journal Articles

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141774

Published: 2020

Journal Articles

In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142314

Published: 2020

Journal Articles

The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL

Jordy C.G. Van Der Zwet, MD, Jessica G.C.A.M. Buijs-Gladdines, Valentina Cordo', MSc, Donna Debets, MSc, Willem K. Smits, Zhongli Chen, MSc, Jelle Dylus, Guido Zaman, PhD, Maarten Altelaar, PhD, Koichi Oshima, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Jan Cools, PhD, Adolfo A. Ferrando, MD PhD, Josef Vormoor, MD PhD, Rob Pieters, MDPhDMSc, Britta Julia Vormoor, MD, Jules P.P. Meijerink, PhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-139305

Published: 2020

Journal Articles

Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group

Mareike Rasche, MD, Emma Steidel, Martin Zimmermann, Jean-Pierre Bourquin, MD PhD, Heidrun Boztug, Iveta Janotová, Edward A. Kolb, MD, Thomas Lehrnbecher, Nils Von Neuhoff, PhD, Naghmeh Niktoreh, Nora Muehlegger, Lucie Sramkova, MD, Jan Stary, MD PhD, Christiane Walter, MSc, Ursula Creutzig, MD PhD, Michael Dworzak, MD PhD, Dirk Reinhardt, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-139317

Published: 2020

Journal Articles

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli, MD, Gerhard Zugmaier, Peter Bader, MD, Sima Jeha, MD, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD, Benoit Brethon, MD, Claudia Rossig, Christiane Chen-Santel

Blood (2019) 134 (Supplement_1): 1294.

https://doi.org/10.1182/blood-2019-121615

Published: 2019

Journal Articles

Inducible Phase Separation of GSK3α As a Mechanism for Asparaginase Resistance in Acute Leukemias

Laura Hinze, Sabine Schreek, Andre Zeug, PhD, Evgeni Ponimaskin, PhD, Roxane Labrosse, MD FRCPC, James Degar, Gabriela Chiosis, PhD, Sung-Yun Pai, MD, Kristen E. Stevenson, MS, Donna S Neuberg, ScD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Martin Stanulla, MD, Alejandro Gutierrez, MD

Blood (2019) 134 (Supplement_1): 169.

https://doi.org/10.1182/blood-2019-126633

Published: 2019

Journal Articles

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Seth E Karol, MD, Todd M Cooper, DO, Henrique Bittencourt, Lia Gore, MD, Maureen M O'Brien, MD, Christopher Fraser, MD, Marion Gambart, MD, Gunnar Cario, MD PhD, Christian Michel Zwaan, MD PhD, Jean-Pierre Bourquin, MD PhD, Mignon L. Loh, MD, Hubert Caron, MD PhD, Betty Prine, Ahmed Hamed Salem, PhD FCP, Kristina Unnebrink, Bo Tong, PhD, Tammy Palenski, PhD, Andrew E. Place, MD PhD

Blood (2019) 134 (Supplement_1): 2649.

https://doi.org/10.1182/blood-2019-129805

Published: 2019

Journal Articles

STAT3 Is Activated By DYRK1A and Is a Potential Therapeutic Target in B-ALL

Malini Rammohan, MS, Rahul S. Bhansali, Yi-Chien Tsai, Alexander Dong, Sebastien Malinge, PhD, Jean-Pierre Bourquin, MD PhD, John D. Crispino, PhD MBA

Blood (2018) 132 (Supplement 1): 3898.

https://doi.org/10.1182/blood-2018-99-115429

Published: 2018

Journal Articles

The Chromosome 21 Kinase DYRK1A and Its Substrate FOXO1 Constitute a Novel Therapeutic Pathway in B-ALL

Rahul S. Bhansali, Malini Rammohan, MS, Ji Heon Paul Lee, MD PhD, Sebastien Malinge, PhD, Yi-Chien Tsai, Nobuko Hijiya, MD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Corinne Fruit, Thierry Besson, PhD, John D. Crispino, PhD MBA

Blood (2018) 132 (Supplement 1): 548.

https://doi.org/10.1182/blood-2018-99-119854

Published: 2018

Journal Articles

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Fotini Vogiatzi, PhD, Julia Heymann, Thies Rösner, PhD, Lennart Lenk, PhD MSc, Gunnar Cario, MD, Martin Schrappe, MD PhD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Simon Bomken, MD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2018) 132 (Supplement 1): 4177.

https://doi.org/10.1182/blood-2018-99-114677

Published: 2018

Journal Articles

High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study

Franco Locatelli, Gerhard Zugmaier, Peter Bader, MD PhD, Sima Jeha, MD, Paul-Gerhardt Schlegel, MD, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD PhD, Benoit Brethon, Claudia Rossig, MD, Christiane Chen-Santel, MD

Blood (2018) 132 (Supplement 1): 1375.

https://doi.org/10.1182/blood-2018-99-109855

Published: 2018

Journal Articles

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Blood (2018) 132 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2018-99-118255

Published: 2018

Journal Articles

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Blood (2018) 132 (Supplement 1): 2826.

https://doi.org/10.1182/blood-2018-99-117978

Published: 2018

Journal Articles

Outcome of Children Relapsing after First Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia: A Retrospective I-BFM Analysis of 336 Children between 2005 and 2016

Blood (2017) 130 (Supplement 1): 272.

https://doi.org/10.1182/blood.V130.Suppl_1.272.272

Published: 2017

Journal Articles

PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia

Blood (2017) 130 (Supplement 1): 2723.

https://doi.org/10.1182/blood.V130.Suppl_1.2723.2723

Published: 2017

Journal Articles

Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion

Blood (2017) 130 (Supplement 1): 2726.

https://doi.org/10.1182/blood.V130.Suppl_1.2726.2726

Published: 2017

Journal Articles

TCF3-Hlf Hijacks ERG to Activate Leukemia-Critical Super-Enhancers in t(17;19) Leukemia

Yun Huang, PhD, Brice Mouttet, Hans-Jörg Warnatz, PhD, Maria Pamela Dobay, PhD, Blerim Marovca, Silvia Jenni, PhD, Martin Schrappe, MD PhD, Martin Stanulla, MD PhD, Marie-Laure Yaspo, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD

Blood (2017) 130 (Supplement 1): 561.

https://doi.org/10.1182/blood.V130.Suppl_1.561.561

Published: 2017

NARROW

Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL

Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Inducible Phase Separation of GSK3α As a Mechanism for Asparaginase Resistance in Acute Leukemias

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

STAT3 Is Activated By DYRK1A and Is a Potential Therapeutic Target in B-ALL

The Chromosome 21 Kinase DYRK1A and Its Substrate FOXO1 Constitute a Novel Therapeutic Pathway in B-ALL

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Outcome of Children Relapsing after First Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia: A Retrospective I-BFM Analysis of 336 Children between 2005 and 2016

PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia

Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion

TCF3-Hlf Hijacks ERG to Activate Leukemia-Critical Super-Enhancers in t(17;19) Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only